SRR10900583
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
- TNFA_SIGNALING_VIA_NFKB+0.200
- ANDROGEN_RESPONSE+0.100
- APOPTOSIS+0.100
- COMPLEMENT+0.100
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- OXIDATIVE_PHOSPHORYLATION-0.500
- ADIPOGENESIS-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- GLYCOLYSIS-0.400
- HYPOXIA-0.400
- MYC_TARGETS_V1-0.400
- MYOGENESIS-0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | be8d8236-4ebc-46de-a4fd-a901fec1cdce | — | — | 0.914 |
| 2 | SAMN03290886 | — | — | 0.902 |
| 3 | 6b907244-c173-4e29-a163-24258a430477 | — | — | 0.888 |
| 4 | TCGA-ZF-A9R7-01A-11R-A38B-07 | — | — | 0.887 |
| 5 | SRR8518220 | — | D | 0.882 |
| 6 | TCGA-AO-A0JC-01A-11R-A056-07 | — | D | 0.871 |
| 7 | SRR8942978 | — | — | 0.870 |
| 8 | 362a2015-1791-4934-be81-df39540b38ff | — | — | 0.865 |
| 9 | MBCProject_1819_T2B_RNA | — | D | 0.860 |
| 10 | SRR2932840 | — | — | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |